Breaking News

Merck KGaA to Acquire Gamma Biosciences’ Mirus Bio for $600M

Gains portfolio of RUO and GMP reagents and enhancers for a variety of applications from research through virus manufacturing at scale.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck KGaA, Darmstadt, Germany has entered an agreement to acquire Gamma Biosciences operating company, Mirus Bio, for $600 million in cash. Mirus Bio is a provider of innovative transfection solutions used for the delivery of genetic material into cells. The company offers a comprehensive portfolio of RUO and GMP reagents and enhancers based on its multi-component technology. Its products are designed to provide high-performance and cost-effective transfection for a variety of applications, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters